Maxim Group analyst Michael Okunewitch maintained a Buy rating on Mind Medicine (MNMD – Research Report) yesterday and set a price target of $18.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Michael Okunewitch has given his Buy rating due to a combination of factors including MindMed’s robust financial position and strategic focus on addressing brain health disorders. The company reported a strong cash reserve of $246 million, which is expected to sustain operations well into 2027, surpassing the anticipated Phase 3 data readouts for their generalized anxiety disorder (GAD) program in the first half of 2026.
Furthermore, MindMed’s ongoing Phase 3 programs targeting both GAD and major depressive disorder (MDD) present a competitive edge, as these conditions often coexist, potentially allowing MM120 to serve as a comprehensive treatment option. The company’s proactive steps towards commercialization, such as hiring a seasoned Chief Commercial Officer with relevant experience, further bolster confidence in its future prospects.
In another report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $20.00 price target.